Antares Pharma Inc (ATRS)

2.73
0.01 0.55
NASDAQ : Health Care
Prev Close 2.74
Open 2.77
Day Low/High 2.69 / 2.77
52 Wk Low/High 0.67 / 2.25
Volume 410.12K
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 155.24M
Market Cap 428.47M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks Under $10 Weekly Summary

We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.

Quarter Gives Antares Pharma a 'QuickShot'

With the stock jumping on 4Q results, we'll lower our rating.

Stocks Under $10 Weekly Summary

We bulked up on Abraxas Petroleum and Yamana Gold on weakness, as the markets pulled back and investors positioned for next week’s FOMC meeting.

Stocks Under $10 Weekly Summary

We booked some profits in Huntington Bancshares and Builders FirstSource, while markets digested the likelihood of a March rate hike.

Stocks Under $10 Weekly Summary

We opened a new position in Abraxas Petroleum on its above-average growth potential, as stocks faced selling pressure this week.

Stocks Under $10 Weekly Summary

We closed out our position in OraSure Technologies for an average gain of 105% gain.

Stocks Under $10 Weekly Summary

We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.

Injecting Some Testosterone Into the Portfolio

We're initiating a position in drug-delivery system developer Antares Pharma, which we think can double from current levels.

2 Bargain Stocks Boasting Big Insider Buys

While there are many reasons why insiders may sell a stock, there's really only one reason they purchase on the open market -- to make money.

Antares Pharma Announces Submission Of New Drug Application For Quickshot® Testosterone

Antares Pharma Announces Submission Of New Drug Application For Quickshot® Testosterone

The Company's First New Drug Application Utilizing QuickShot® Technology

First Week of August 2017 Options Trading For Antares Pharma (ATRS)

First Week of August 2017 Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options begin trading this week, for the August 2017 expiration.

Antares Pharma Announces The Successful Completion Of Teva's Decentralized Procedure For Teriparatide Injection In Europe

Antares Pharma Announces The Successful Completion Of Teva's Decentralized Procedure For Teriparatide Injection In Europe

Teriparatide Injection Represents the First Product Approved in Europe Utilizing Antares' Multi-Dose Pen Technology

Antares Pharma Reports Third Quarter 2016 Financial And Operating Results

Antares Pharma Reports Third Quarter 2016 Financial And Operating Results

Record Product Sales Drive Third Quarter Results

Antares Pharma Announces Multiple Presentations At The Sexual Medicine Society Scientific Annual Meeting

Antares Pharma Announces Multiple Presentations At The Sexual Medicine Society Scientific Annual Meeting

QuickShot® Testosterone Data Has Been Selected for Both Oral and Poster Presentations

Antares Pharma Announces Completion Of The QuickShot Testosterone Clinical Program

Antares Pharma Announces Completion Of The QuickShot Testosterone Clinical Program

Analysis of 26 Week Safety Data From Study QST-15-005 Completed, NDA Submission Remains on Track for Fourth Quarter 2016

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Antares Pharma Reports Second Quarter 2016 Operating And Financial Results

Antares Pharma Reports Second Quarter 2016 Operating And Financial Results

Significant Growth in Product Sales Drive Second Quarter Results